Physicians' Academy for Cardiovascular Education

Tackling risk reduction in ASCVD: A clinical case

10' education - Dec. 5, 2022 - Prof. Lawrence Leiter, MD

Mechanistic clues to understanding the benefits of icosapent ethyl

10' education - Nov. 28, 2022 - Prof. Matthew Budoff, MD

Long-term efficacy and safety of intravenous iron in HF

3' education - Nov. 21, 2022 - Paul R. Kalra

Applying GDMT for iron deficiency in heart failure

10' education - Nov. 17, 2022 - Prof. Piotr Ponikowski, MD, PhD, Adrian F. Hernandez, MD, Prof. Andrew Sindone, MD

Maximally tolerated or suboptimal therapy? Clinical perspectives on rechallenging RAASi therapy

10' education - Nov. 17, 2022 - Prof. Ileana L. Piña, MD & Prof. Patrick Rossignol, MD, PhD

Identifying and treating iron deficiency in heart failure

10' education - Nov. 17, 2022 - Robert J. Mentz, MD & Prof. Peter van der Meer, MD, PhD

Looking beyond diabetes: The role of SGLT2i and MRAs in cardiorenal disease

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD

Why ischemia matters when it comes to iron deficiency in heart failure

10' education - Nov. 17, 2022 - Prof. Marco Metra, MD & Prof. Piotr Ponikowski, MD, PhD

How to choose the optimal therapy?

10' education - Nov. 17, 2022 - Prof. Kausik Ray, MD

The role of potassium binders in optimal HF management: Discussing the DIAMOND study

10' education - Nov. 17, 2022 - Prof. Ileana L. Piña, MD, Prof. Stefan D. Anker, MD, PhD, Prof. Javed Butler, MD, Prof. Bertram Pitt, MD

New perspectives in managing heart failure and hyperkalemia – The cardiorenal angle

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD & Prof. Austin G. Stack, MD

Addressing late-breaking data on triglycerides, fibrates and omega-3FAs

15' education - Nov. 16, 2022 - Prof. Peter Libby, MD, Prof. Gabriel Steg, MD, Prof. Kausik Ray, MD

Reducing morbidity and mortality in patients with CKD and T2DM

10' education - Nov. 14, 2022 - Pam Taub, MD, Prof. George Bakris, MD, and Prof. Gerasimos Filippatos, MD

A new option for cardiorenal protection for patients with CKD and T2DM

10' education - Nov. 14, 2022 - Prof. Gerasimos S. Filippatos, MD, Javier Morales, MD, and Angela Yee-Moon Wang, MD, PhD

Effects of a guideline-based approach on achieving LDL-c goals

3' education - Nov. 14, 2022 - Aaram Omar Khader, MD

LDL-c: new insights into its role as causal risk factor and target for therapy

10' education - Nov. 11, 2022 - Prof. Brian Ference, MD

Improved outcomes with rapid uptitration of HF medication after acute HF

3' education - Nov. 8, 2022 - Prof. Alexandre Mebazaa, MD, PhD

Low-dose statin lowers LDL-c more than dietary supplements

3' education - Nov. 8, 2022 - Luke J. Laffin, MD

Dramatic reduction in primary endpoint with precision testing in stable patients with suspected CAD

3' education - Nov. 7, 2022 - Prof. Pamela Douglas, MD

Is one diuretic better than the other diuretic in veterans with hypertension?

3' education - Nov. 7, 2022 - Areef Ishani, MD

Long -term data show blood pressure reductions with renal artery denervation procedure

Literature - Dec. 6, 2022 - Bhatt DL, et al. - The Lancet. 2022

The long-term follow-up of patients with uncontrolled, treatment-resistant hypertension, treated with renal denervation demonstrated larger and sustained reductions in SBP when compared with a sham procedure, as shown by the final results from the SYMPLICITY HTN-3 trial.

Background MRA or ARNI does not alter efficacy and safety of SGLT2i in HFmrEF/HFpEF

Literature - Dec. 6, 2022 - Yang M, et al. - Eur J Heart Fail. 2022

In patients with HFmrEF or HFpEF, the efficacy and safety of dapagliflozin were not influenced by background treatment with an MRA or ARNI, as shown by a prespecified analysis of the DELIVER trial.

Higher Lp(a) in children with clinical presentation of FH but no genetic mutation

Literature - Dec. 6, 2022 - De Boer LM, et al. - Eur Heart J. 2022

A Dutch cross-sectional study showed that Lp(a) levels were higher and more often elevated in children with a clinical presentation of FH in whom no FH-causing mutation was detected compared with children with a mutation and their unaffected siblings.

Monotherapy with oral anticoagulant beyond 1 year after PCI as effective and safe as dual therapy in stable AF patients

Literature - Dec. 5, 2022 - Jensen T, et al. - Eur Heart J Cardiovasc Pharmacother. 2022

European AF guidelines recommend treating patients with stable AF and an increased risk of stroke beyond 1 year after PCI with anticoagulant monotherapy, rather than dual therapy with an oral anticoagulant and antiplatelet drug. However, the evidence for this is scarce.

Tackling risk reduction in ASCVD: A clinical case

10' education - Dec. 5, 2022 - Prof. Lawrence Leiter, MD
Prof. Leiter presents a case of a patient with high CV risk despite LDL-c lowering with statin therapy. He explains why this patient may benefit from treatment with icosapent ethyl.

Prof. Leiter presents a case of a patient with high CV risk despite LDL-c lowering with statin therapy. He explains why this patient may benefit from treatment with icosapent ethyl.

ASCVD history does not modify nonsteroidal MRA’s cardiorenal effects in T2DM and CKD

Literature - Nov. 29, 2022 - Filippatos G, et al. - Eur Heart J Cardiovasc Pharmacother. 2022

Irrespective of a history of ASCVD, finerenone reduced the risk of CV events and CKD progression compared with placebo in patients with T2DM and CKD, as shown in a FIDELITY subgroup analysis.

Low adherence and persistence with HF therapies in new-onset HF

Literature - Nov. 29, 2022 - Ødegaard KM, et al. - ESC Heart Fail. 2022

A Norwegian nationwide cohort study showed that in newly diagnosed HF patients, 1-year adherence to dual or triple HF therapies was low and 2- to 5-year persistence was inadequate.

Mechanistic clues to understanding the benefits of icosapent ethyl

10' education - Nov. 28, 2022 - Prof. Matthew Budoff, MD
Mechanistic studies on plaque characteristics in patients receiving EPA can be insightful to understand the CV risk reductions seen in clinical trials. Prof. Budoff gives an overview of effects of EPA on multiple plaque components.

Mechanistic studies on plaque characteristics in patients receiving EPA can be insightful to understand the CV risk reductions seen in clinical trials. Prof. Budoff gives an overview of effects of EPA on multiple plaque components.

Morning physical activity associated with reduced CVD risk

Literature - Nov. 28, 2022 - Albalak G, et al. - Eur J Prev Cardiol. 2022

Sufficient physical activity lowers the risk of CV mortality and improves quality of life. However, little is known about the association between timing of physical activity and CVD risk in the general population.

Efficacy and safety of PCSK9 siRNA in primary prevention cohort

Literature - Nov. 23, 2022 - Ray KK, et al. - Eur Heart J. 2022

In an ORION-11 substudy, inclisiran reduced LDL-c, non-HDL-c and apoB levels in a subgroup of high-risk patients with elevated LDL-c but without prior CV events receiving maximally tolerated statin therapy.

Beneficial effects of non-steroidal MRA on HF-related outcomes in CKD and T2DM

Literature - Nov. 22, 2022 - Filippatos G, et al. - JACC Heart Fail. 2022

Finerenone, a non-steroidal MRA, has been approved for the treatment of CKD in adults with T2DM. Previously, the FIDELITY study showed that finerenone improves cardiorenal outcomes in these patients. But does this also apply to HF-related outcomes?

SGLT2 inhibition leads to early decongestion and clinical benefit in acute HF

Literature - Nov. 22, 2022 - Biegus J, et al. - Eur Heart J. 2022

In 530 patients hospitalized for acute HF, empagliflozin treatment resulted in early, clinically meaningful decongestion compared with placebo. The magnitude of decongestion was associated with clinical benefit at day 90.

Agenda